Analyst Moves: BIIB, X, PFE - Presented by: The Aol. On Network

This morning, Goldman Sachs downgraded shares of Biogen (BIIB) from buy to neutral citing valuation. The stock has reached the firm's $215 price target, leaving less upside for investors.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 16.775 0.11 ▲ 0.63%
GRPN $ 5.94 0.09 ▼ 1.49%
FB $ 82 1.56 ▲ 1.93%
INTC $ 32.96 0.31 ▼ 0.93%
FTR $ 5.305 0.15 ▲ 2.81%
AAPL $ 130.49 0.53 ▲ 0.41%
WEN $ 11.53 0.43 ▲ 3.87%
PBR $ 8.90 0.02 ▼ 0.22%

As of 6/3/2015, 10:02 AM